Researchers at The University of Texas MD Anderson Cancer Centre have shed new light on why pancreatic tumours are so resistant to therapy.

The answer may lie in treating a protein found in the scar-type tissue called stroma which often surrounds the tumours.

The tumour-associated stroma is comprised mostly of pancreatic stellate cells (PSCs) and its density and possibly the cells themselves are thought to prevent current treatments from effectively killing the tumour.

Dickkopf-3 (DKK3), is produced by the stromal cells but acts on the neighbouring cancer cells to increase their growth, metastasis and resistance to therapy.

DKK3 has been identified as a potential target for treatment with a newly developed DKK3-blocking antibody, according to results from a study led by Rosa Hwang, M.D., professor in Surgical Oncology and Breast Surgical Oncology.

Findings are published in Science Translational Medicine.

Hwang's lab found DKK3 to be highly expressed in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and specifically by PSCs rather than cancer cells, and her team discovered different ways to silence DKK3 from acting on cancer cells as well as immune cells in the tumour microenvironment.

The researchers developed an antibody to block the DKK3 molecule in mice, which not only inhibited tumour growth but also significantly prolonged life.

"Pancreatic cancer has a dismal prognosis and it is unclear if its stromal infiltrate contributes to its aggressiveness.We demonstrated that DKK3 is produced by PSCs and is present in the majority of human pancreatic cancer," said Hwang. "DKK3 stimulates cancer growth, metastasis, and resistance to chemotherapy and immunotherapy. Targeting DKK3 in a pancreatic cancer mouse model boosted immune cell infiltration and more than doubled survival."

Hwang's team examined DKK3 expression in human pancreatic tumours and found that at least two-thirds of patients had moderate-to-very strong levels of DKK3.

Compared to normal controls, DKK3 levels were 4.5 times higher in PDAC.

Due to DKK3's dual effects in promotion of tumour growth and in resistance to therapy, Hwang's results indicate that DKK3 is a therapeutic target as either monotherapy or in combination with immunotherapy or chemotherapy.

"Previous efforts to target pancreatic cancer stroma were directed at broadly eliminating stromal elements," she said. "Our study shows that a more effective strategy may be to inhibit specific tumour-promoting mechanisms attributed to PSCs, such as DKK3."

Source: University of Texas MD Anderson Cancer Centre